- Home
- HYFT vs IMUX Comparison
HYFT vs IMUX Comparison
Compare HYFT & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYFT | IMUX |
|---|---|---|
| Founded | 1983 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.4M | 85.8M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | HYFT | IMUX |
|---|---|---|
| Price | $2.28 | $0.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 666.7K | ★ 1.6M |
| Earning Date | 12-15-2025 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,019,110.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $51.71 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 49.46 | N/A |
| 52 Week Low | $0.27 | $0.51 |
| 52 Week High | $3.25 | $1.39 |
Technical Indicators
Market Signals| Indicator | HYFT | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 57.66 |
| Support Level | N/A | $0.59 |
| Resistance Level | N/A | $0.71 |
| Average True Range (ATR) | 0.00 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 76.31 |
Price Performance
Historical ComparisonAbout HYFT MindWalk Holdings Corp.
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.